1514-P: Serum Amylase (AMY) Level and Its Chronological Change as a Predictor of Incident Type 2 Diabetes Mellitus (T2DM)

Low serum AMY is commonly observed in people with a history of pancreatitis, which is a well-known predictor of T2DM. However, few longitudinal studies investigated whether low AMY could be predictive of T2DM, especially considering the effects of baseline HbA1c. Also, it is unclear if a change in AMY is predictive of incident T2DM. Thus, we investigated the impact of AMY and its chronological change on the risk of T2DM considering baseline HbA1c. Analyzed were 5306 individuals who had health examinations yearly for 7 y. We monitored the change in AMY values between baseline 1 (first visit) and baseline 2 (2 y later) and ratio of baseline 2 to baseline 1. During the 5-y follow-up, T2DM occurred in 716 patients. Multivariate Cox analysis showed that both a lower AMY at baseline 2 (HR of Quintile 1, 1.44[1.11-1.88] vs. Q5 as ref.) and a larger AMY decline from baseline 1 (HR of Disclosure D. Ishii: None. K. Fujihara: None. R. Nedachi: None. M. Harada: None. Y. Matsubayashi: None. K. Saito: None. S. Kodama: None. R. Yamamoto-Honda: None. Y. Arase: None. H. Sone: Research Support; Self; Astellas Pharma Inc., Boehringer Ingelheim Pharmaceuticals, Inc., Daiichi Sankyo Company, Limited, Kowa Pharmaceutical Europe Co. Ltd., Kyowa Hakko Kirin Co., Ltd., Novo Nordisk Inc., Ono Pharmaceutical Co., Ltd., Taisho Pharmaceutical Co., Ltd., Takeda Pharmaceutical Company Limited, Teijin Pharma Limited.